An Open-Label, Multi-Centre, Randomised, Switch Study to Evaluate the Virological Efficacy Over 96 Weeks Of 2-Drug Therapy With DTG/RPV FDC in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Resistance Mutation K103N
Latest Information Update: 30 Dec 2024
At a glance
- Drugs Dolutegravir/rilpivirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms WISARD
Most Recent Events
- 02 Dec 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2021 Interim results (n=123) assessing potential to maintain viral suppression with DTG/RPV in subjects with documented K103N currently suppressed on other regimens presented at the 11th International AIDS Society Conference on HIV Science